TL;DR Verdict
Tirzepatide is the active ingredient in both Zepbound and Mounjaro and is the most effective weight loss compound currently available. SURMOUNT trial data published in the New England Journal of Medicine shows 15 to 20.9% body weight reduction depending on dose over 72 weeks. Patient reviews cover both brand-name products and compounded tirzepatide, with compounded versions gaining significant traction among patients seeking more affordable access.
Overall patient satisfaction is high across all forms.
How Effective Is Tirzepatide for Weight Loss?
Tirzepatide produces 15 to 20.9% average body weight loss depending on dose level over 72 weeks, according to the SURMOUNT-1 trial published in the New England Journal of Medicine. It works as a dual GLP-1 and GIP receptor agonist, targeting two incretin pathways simultaneously rather than one, which appears to explain its superior efficacy compared to semaglutide-based medications.
The SURMOUNT trial program is the largest clinical trial program ever conducted for tirzepatide in a non-diabetic obesity population. SURMOUNT-1 enrolled 2,539 participants[2]. SURMOUNT-2 studied patients with both obesity and type 2 diabetes.
SURMOUNT-3 combined tirzepatide with intensive behavioral therapy and produced an average weight loss of 26.6%, the highest figure ever recorded in an anti-obesity medication trial.
For context, tirzepatide outperforms semaglutide 2.4 mg (Wegovy) by approximately 6 percentage points in average weight loss. It also outperforms every older anti-obesity medication by a wide margin. The only compounds showing potentially higher efficacy are still in clinical trials, including retatrutide and survodutide.
| Dose | Avg. Weight Loss | Achieved 5%+ Loss | Achieved 10%+ Loss | Achieved 20%+ Loss |
|---|---|---|---|---|
| 5 mg | 15.0% | 85% | 69% | 34% |
| 10 mg | 19.5% | 89% | 79% | 49% |
| 15 mg | 20.9% | 91% | 84% | 57% |
| Placebo | 3.1% | 35% | 17% | 3% |
The dual mechanism is the key differentiator. GLP-1 activation reduces appetite and slows gastric emptying. GIP activation appears to improve fat metabolism and enhance the body's sensitivity to GLP-1 signaling.
Together, these pathways produce greater weight loss than GLP-1 activation alone.
What Do Patients Report About Tirzepatide?
Patient reviews of tirzepatide across brand-name and compounded forms show satisfaction ratings consistently above 80%, based on aggregated feedback from Drugs.com, WebMD, Reddit communities, and telehealth provider review platforms through early 2026. Patients taking brand-name Zepbound or Mounjaro and those on compounded tirzepatide report similar levels of appetite suppression and weight loss. For a complete cost breakdown, see our see tirzepatide pricing.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
The most common positive feedback centers on the strength of appetite suppression. Patients frequently compare tirzepatide favorably to semaglutide, describing it as "stronger" or "more complete" in eliminating food cravings. Many patients who switched from Wegovy or Ozempic report accelerated weight loss after starting tirzepatide.
Compounded tirzepatide has generated its own category of patient reviews, with many users praising the cost savings while noting that the experience feels clinically similar to brand-name versions. The main concern among compounded tirzepatide users is quality assurance, which varies by pharmacy.
Positive Review Themes
- Powerful appetite control: Patients describe tirzepatide as the most effective appetite suppressant they have ever tried.
- Consistent weight loss: Steady, predictable loss of 1 to 2 pounds per week is commonly reported during therapeutic dosing.
- Blood sugar improvements: Patients with prediabetes or insulin resistance report significant improvements in fasting glucose and A1C.
- Improved relationship with food: Many patients describe feeling "normal" around food for the first time, without obsessive cravings.
- Better sleep and energy: As weight decreases, patients commonly report better sleep quality and higher daytime energy.
Negative Review Themes
- GI side effects during titration: Nausea and diarrhea remain the most common complaints, especially at dose increases.
- Cost barriers: Brand-name tirzepatide is expensive, and not all patients qualify for savings programs.
- Compounding quality concerns: Patients using compounded tirzepatide occasionally report inconsistent potency or injection site irritation.
- Weight regain fears: Patients worry about what happens when they stop, especially given the SURMOUNT-4[1] withdrawal data.
- Muscle loss: Some patients report losing muscle along with fat, particularly those who aren't strength training during treatment.
Tirzepatide Side Effects: What Patients Actually Experience
Tirzepatide side effects are predominantly gastrointestinal, with nausea affecting 18 to 24% of patients, diarrhea affecting 13 to 18%, and constipation affecting 6 to 11% at therapeutic doses, according to FDA prescribing information for both Mounjaro and Zepbound. These rates are modestly lower than those reported for semaglutide 2.4 mg in the STEP trials.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Patient reviews consistently describe a predictable pattern: GI symptoms appear within 2 to 3 days of each dose increase, peak during the first week, and fade by weeks 2 to 3. Patients who follow the recommended titration schedule (starting at 2.5 mg and increasing every 4 weeks) report better tolerability than those who escalate doses faster.
One notable finding from patient communities is that tirzepatide users report slightly less nausea overall compared to semaglutide users. While this observation isn't from a head-to-head clinical trial, the pattern is consistent enough across patient forums and review platforms to be worth noting.
| Side Effect | Brand-Name Incidence | Compounded (Patient-Reported) | Typical Duration |
|---|---|---|---|
| Nausea | 18 to 24% | Similar. some report less | 1 to 3 weeks per dose increase |
| Diarrhea | 13 to 18% | Similar | 1 to 2 weeks |
| Constipation | 6 to 11% | Similar | Variable |
| Decreased appetite | 12 to 20% | Similar | Persistent (desired effect) |
| Injection site reactions | 3 to 7% | Slightly higher reported | Minutes to hours |
| Hair thinning | 5.7% | Similar | Temporary (months 3 to 6) |
| Sulfur burps | Not formally measured | Commonly reported | Variable. diet-dependent |
Serious side effects remain rare across all tirzepatide formulations. Pancreatitis occurred in less than 0.3% of trial participants. The boxed warning about thyroid C-cell tumors is based on animal studies, with no confirmed human cases to date.
Compounded Tirzepatide Reviews: What Patients Say
Compounded tirzepatide has become a major category within the broader tirzepatide review space, with providers like FormBlends offering it at $149 per month compared to roughly $1,060 for brand-name versions. Patient reviews of compounded tirzepatide are generally positive, with most users reporting weight loss and appetite suppression comparable to brand-name Mounjaro or Zepbound.
The primary advantage cited by patients is cost. At $149 per month through providers like FormBlends, compounded tirzepatide costs roughly 85% less than the brand-name list price. For patients without insurance coverage for Zepbound or Mounjaro, compounded versions make the medication accessible.
The primary concern is consistency. Compounded medications are prepared by 503A or 503B compounding pharmacies, which are regulated by state boards of pharmacy and, in the case of 503B facilities, by the FDA. Patients report that quality is generally high when sourced through reputable telehealth providers, though some have experienced batch-to-batch variation in injection smoothness.
Disclosure: FormBlends is a licensed telehealth provider that offers compounded tirzepatide at $149/month. This article is an independent drug review, and our clinical assessments are based on published trial data regardless of the medications we offer.
What Compounded Tirzepatide Patients Report
- Cost savings: The most praised aspect is affordability, with patients frequently noting they couldn't access tirzepatide without compounded options.
- Medical oversight: Patients value that reputable compounded tirzepatide providers include prescriber consultations and dosing guidance.
- Comparable results: Most patients report weight loss trajectories similar to what clinical trials show for brand-name tirzepatide.
- Injection differences: Some patients note that compounded tirzepatide (typically supplied in vials with syringes) feels different from the brand-name autoinjector pens.
- Regulatory uncertainty: Some patients express concern about the long-term availability of compounded tirzepatide given evolving FDA regulations around compounding.
| Feature | Brand-Name (Zepbound/Mounjaro) | Compounded (e.g., FormBlends) |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| FDA-approved | Yes | No (compounded under pharmacy regulations) |
| Monthly cost | ~$1,060 (no insurance) | ~$149/mo |
| Delivery method | Autoinjector pen | Vial + syringe (typically) |
| Medical oversight | Via prescribing provider | Included with telehealth consultation |
| Available doses | 2.5 to 15 mg (fixed pens) | Customizable dosing |
| Insurance eligible | Yes (if covered) | Generally not covered |
How Does Tirzepatide Compare to Other Weight Loss Drugs?
Tirzepatide produces the highest average weight loss of any FDA-approved weight loss compound, at 20.9% on the 15 mg dose compared to 14.9% for semaglutide 2.4 mg and roughly 5 to 10% for older medications, according to published trial data in the New England Journal of Medicine. Its dual GLP-1/GIP mechanism sets it apart from single-target drugs.
The main competitor is semaglutide, which powers both Wegovy and Ozempic. While semaglutide produces less weight loss on average, it has the SELECT cardiovascular outcomes trial showing a 20% reduction in major cardiac events. Tirzepatide cardiovascular[3] outcomes data is still being studied.
Pipeline drugs like retatrutide (a triple agonist targeting GLP-1, GIP, and glucagon receptors) have shown even higher weight loss in early trials, but none are yet FDA-approved.
| Medication | Active Ingredient | Mechanism | Avg. Weight Loss | Monthly Cost (no insurance) |
|---|---|---|---|---|
| Zepbound/Mounjaro | Tirzepatide | GLP-1 + GIP dual agonist | 20.9% | ~$1,060 |
| Compounded tirzepatide | Tirzepatide | GLP-1 + GIP dual agonist | Comparable (patient-reported) | ~$149 |
| Wegovy | Semaglutide 2.4 mg | GLP-1 agonist | 14.9% | ~$1,350 |
| Ozempic | Semaglutide 1.0 mg | GLP-1 agonist | ~10% (off-label) | ~$950 |
| Saxenda | Liraglutide | GLP-1 agonist | 8% | ~$1,350 |
| Contrave | Naltrexone/bupropion | Opioid antagonist + antidepressant | 5 to 6% | ~$300 |
For detailed comparisons, see our semaglutide vs. alternatives guide and our complete tirzepatide for weight loss overview.
Frequently Asked Questions About Tirzepatide
Is tirzepatide the same as Zepbound and Mounjaro?
Yes. Tirzepatide is the active pharmaceutical ingredient in both Zepbound and Mounjaro. Zepbound is approved for weight management and Mounjaro for type 2 diabetes, but the medication itself is identical.
Compounded tirzepatide also contains compounded formulations of the active ingredient.
How much weight can you lose on tirzepatide?
The SURMOUNT-1 trial[2] showed average weight loss of 15 to 20.9% depending on dose over 72 weeks. The 15 mg dose produced the highest results, with 57% of participants losing 20% or more of their body weight.
Is compounded tirzepatide safe?
Compounded tirzepatide prepared by licensed 503A or 503B pharmacies under proper oversight is generally considered safe. But compounded medications aren't individually FDA-approved, and quality can vary. Choosing a reputable provider that sources from inspected pharmacies is important.
What are the side effects of tirzepatide?
The most common side effects are nausea (18 to 24%), diarrhea (13 to 18%), and constipation (6 to 11%). These are typically mild to moderate and improve within a few weeks of each dose increase. Serious side effects like pancreatitis are rare.
How much does compounded tirzepatide cost?
Compounded tirzepatide typically costs $149 to $399 per month depending on the provider and dose. FormBlends offers it starting at $149/month with medical provider oversight included. Brand-name versions (Zepbound/Mounjaro) list at approximately $1,060/month without insurance.
How does tirzepatide compare to semaglutide?
Tirzepatide produces approximately 6 percentage points more weight loss than semaglutide on average (20.9% vs. 14.9%). Tirzepatide targets both GLP-1 and GIP receptors, while semaglutide targets only GLP-1.
Semaglutide has stronger cardiovascular outcomes data from the SELECT trial[3].
Can you switch from semaglutide to tirzepatide?
Yes. Many patients switch from semaglutide to tirzepatide and report improved results. Your provider will determine the appropriate starting dose based on your current semaglutide dose and response.
Most providers recommend a brief overlap period or direct switch.
How long do you need to take tirzepatide?
Tirzepatide is intended as long-term treatment. The SURMOUNT-4 trial showed that patients who discontinued tirzepatide regained an average of 14% of their body weight within a year. Most providers recommend ongoing use alongside sustainable lifestyle habits.
For more resources, explore our Zepbound before-and-after results, detailed tirzepatide side effects guide, and tirzepatide cost without insurance breakdown.
Medical References
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. [PubMed | ClinicalTrials.gov | DOI]
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →